Industry Program

Industry Program

What are industry symposia?

Industry symposium sessions offer pertinent data on the latest scientific information and developments from the industry. Hear from leading experts on the latest advances in nephrology practices, therapies, services, and technologies in Industry symposia are not organized by ISN and are not accredited with CME through WCN. Organizers may offer separate accreditation for their session.

How can I watch these sessions?

The industry sessions are available on-demand on the event platform until May 31, 2021. They will then move to the ISN Academy for viewing.

Sessions are open-access so there is no registration fee. If you are not registered already to WCN’21, you must complete a registration form before you can access and input the unique code for the session you want to view.

Step 1: Register with unique code for free access to session
Step 2: View session on-demand

Industry Symposia Program (Friday, April 16, 2021)

  • Contemporary concepts in ADPKD: Innovations in clinical practice and novel disease mechanisms
  • Organizer:  Sanofi Genzyme
  • Room: Room 5
  • Time: 11:00 – 12:00 EDT
  • Chair: Lanktree, Matthew (Canada)
  • OPEN ACCESS CODE: AUYIMR05
  • Schedule:
    Time Title Speaker
    11:00 – 11:02 Welcome and Introduction Lanktree, Matthew (Canada)
    11:02 – 11:10 Insights into ADPKD from genetic studies Lanktree, Matthew (Canada)
    11:10 – 11:35 Clinical practice update and case presentations in ADPKD Pei, York (Canada)
    11:35 – 11:50 Novel disease mechanisms in ADPKD Maski, Manish (United States)
    11:50 – 12:00 Q&A All Faculty

  • Why Target the Mucosal Immune System of the Gut to Treat IgA Nephropathy?
  • Organizer: Calliditas Therapeutics
  • Room: Room 2
  • Time: 11:00 – 12:00 EDT
  • Chair: Barratt, Jonathan (United Kingdom)
  • OPEN ACCESS CODE: ZUYIMR01
  • Schedule:
    Title Speaker
    11:00 – 11:05 Welcome and introductions Barratt, Jonathan (United Kingdom)
    11:05 – 11:20 Targets for new drug development in IgAN Rovin, Brad (United States)
    11:20 – 11:35 The rationale for targeting the mucosal immune system in IgAN Barratt, Jonathan (United Kingdom)
    11:35 – 11:50 Clinical experience of targeting the Peyer’s patches in IgAN Lafayette, Richard (United States)
    11:50 – 12:00 Q+A Barratt, Jonathan (United Kingdom)

  • Nonsteroidal MRAs: A new chapter for the management of CKD in T2D
  • Organizer: Bayer AG
  • Room: Room 3
  • Time: 11:00 – 12:00 EDT
  • Chair: Pecoits-Filho, Roberto (United States)
  • OPEN ACCESS CODE: ZUYIMR00
  • Schedule:
    Time Title Speaker
    11:00 – 11:05 Welcome and introductions Pecoits-Filho, Roberto (United States)
    11:05 – 11:25 Inflammation and fibrosis as a driver of CKD progression: An opportunity for intervention? Cherney, David (Canada)
    11:25 – 11:45 Impact of MR antagonism in CKD in T2D: Lessons from the FIDELIO-DKD trial Bakris, George (United States)
    11:45 – 11:55 Q+A All Faculty
    11:55 – 12:00 Summary + Close Pecoits-Filho, Roberto (United States)

  • Proteinuria Treatment Targets in Glomerular Disease: Providing Insights into Clinical Outcomes
  • Organizer: Travere Therapeutics
  • Room: Room 1
  • Time: 11:00 – 12:30 EDT
  • Chair: Barbour, Sean (Canada)
  • OPEN ACCESS CODE: RUYIMR04 
  • Schedule:
    Time Title Speaker
    11:00 – 11:10 Introduction and setting the scene Barbour, Sean (Canada)
    11:10 – 11:25 Proteinuria targets in FSGS Mariani, Laura (United States)
    11:25 – 11:35 Proteinuria targets in IgAN Barbour, Sean (Canada)
    11:35 – 11:45 Proteinuria as surrogate endpoint for regulatory approval of novel therapeutics in glomerular disease Carroll, Kevin J. (United Kingdom)
    11:45 – 12:00 Close, Q+A and integrated polling All Faculty
    12:00 – 12:30
    Breakout Room 

Industry Symposia Program (Saturday, April 17, 2021)

  • The Challenge of Slowing Diabetic Kidney Disease Progression And Reducing Cardiovascular Risk: Recent Advances and Novel Strategies
  • Provider: Cardiometabolic Health Congress      Supported by an unrestricted educational grant from Bayer Healthcare Pharmaceuticals Inc
  • Room: Room 5
  • Time: 11:00 – 12:00 EDT
  • Chair: Bakris, George L. (United States)
  • OPEN ACCESS CODE: ERBEDX99
  • Schedule:
    Time Title Speaker
    11:00 – 11:15 Introduction, Background and Future of DKD Bakris, George L. (United States)
    11:15 – 11:30 New Perspectives in the Management of CKD in T2D: the Emerging Role of MRAs Agarwal, Rajiv (United States)
    11:15 – 11:30 Effect of Finerenone on CKD Outcomes in T2D Bakris, George L. (United States)
    11:30 – 11:45 Finerenone and Cardiovascular Outcomes Filippatos, Gerasimos (Greece)
    11:45 – 12:00 Panel Discussion, Q+A and Closing All Faculty

  • SGLT2 inhibitors: The next step to optimal care in CKD
  • Supported by an unrestricted educational grant from AstraZeneca
  • Room: Room 1
  • Time: 11:00 – 12:00 EDT
  • Chair: Tuttle, Katherine (United States)
  • OPEN ACCESS CODE: RUYIMR99
  • Schedule:
    Time Title Speaker
    11:00 – 11:05 Welcome and Introduction Tuttle, Katherine (United States)
    11:05 – 11:20 Impacting clinical practice – SGLT2 inhibitors in CKD Correa-Rotter, Ricardo (Mexico)
    11:20 – 11:35 How SGLT2 inhibitors fit in the CKD management framework Cherney, David (Canada)
    11:35 – 11:50 Initiating SGLT2 inhibitors – the cardiologist’s experience Jhund, Pardeep (United Kingdom)
    11:50 – 12:00 Evidence in practice, Q+A and panel discussion All Faculty
    12:00 – 12:30
    Breakout Room 

  • Kidney itch: what’s new and what to do
  • Organizer: Connect2 CME        Supported by an unrestricted educational grant from Vifor Fresenius Medical Care Renal Pharma
  • Room: Room 4
  • Time: 11:00 – 12:00 EDT
  • Chair: Rayner, Hugh (United Kingdom)
  • OPEN ACCESS CODE: RUYIMR01
  • Schedule:
    Title Speaker
    11:00 – 11:05 Welcome and Introduction Rayner, Hugh (United Kingdom)
    11:05 – 11:10 A patient’s experience
    11:10 – 11:20 The burden and impact of kidney itch worldwide Sukul, Nidhi (United States)
    11:20 – 11:30 Why do kidney patients itch? Rigatto, Claudio (Canada)
    11:30 – 11:40 An evidence-based approach to managing kidney itch in your patients Rayner, Hugh (United Kingdom)
    11:40 – 12:00 Quiz and patient video
    Interactive Q+A
    Closing remarks

  • A discussion with KDIGO: Individual optimization of management of CKD patients with diabetes and CVD comorbidities
  • Supported by an unrestricted educational grant from the Boehringer Ingelheim and Lilly Alliance
  • Room: Room 3
  • Time: 11:00 – 12:00 EDT
  • Chair: Wanner, Christoph (Germany)
  • OPEN ACCESS CODE: AUYIMR01
  • Schedule:
    Title Speaker
    Welcome and Introductions Wanner, Christoph (Germany)
    11:00 – 11:15 SGLT2 inhibitors and GLP-1 receptor agonists: Different classes, different modes of kidney protection Lambers Heerspink, Hiddo (The Netherlands)
    11:15 – 11:30 Case 1: Kidney benefits associated with current pharmacotherapies in patients with CKD and diabetes Rossing, Peter (Denmark)
    11:30 – 11:45 Case 2: Cardiovascular benefits associated with current pharmacotherapies in patients with CKD and diabetes Michos, Erin (United States)
    11:45 – 12:00 Panel discussion All Faculty

Industry Symposia Program (Sunday, April 18, 2021)

  • Treating Anemia of CKD: Real-World Clinical Experience with HIF-PH Inhibitors
  • Supported by an unrestricted educational grant from AstraZeneca
  • Room: Room 1
  • Time: 11:00 – 12:00 EDT
  • Chairs: Levin, Adeera (Canada) + Hao, Chuan-Ming (China)
  • OPEN ACCESS CODE: ZUYIMR99
  • Schedule:
    Time Title Speaker
    11:00 – 11:15 Welcome and Introduction Levin, Adeera (Canada)
    Hao, Chuan-Ming (China)
    11:15 – 11:35 HIF-PH inhibitors: Evidence from clinical trials Provenzano, Robert (United States)
    11:35 – 11:50 My clinical experience with HIF-PH inhibitors Hao, Chuan-Ming (China)
    11:50 – 12:00 Chairs’ summary and Q+A
    12:00 – 12:30
    Breakout Room

  • Fabry Disease: An Unexpected Cause of Renal Disease
  • Provider: Excel CME        Supported by an unrestricted educational grant from Sanofi Genzyme
  • Room: Room 2
  • Time: 11:00 – 12:00 EDT
  • Chairs: Mauer, Michael (United States) + Ortiz, Alberto (Spain)
  • OPEN ACCESS CODE: AUYIMR99
  • Schedule:
    Time Title Speaker
    11:00 – 11:30 Overview of Fabry Disease: Classic vs Non-Classic Mauer, Michael (United States)
    Renal Manifestations: Biomarkers, Clinical, Kidney Pathology, Evaluation
    11:30 – 12:00 Evidence-based Long-term Disease Management Therapy Ortiz, Alberto (Spain)
    Current and Emerging Therapies and Treatment Recommendations
    12:00 – 12:30
    Breakout Room

    (Q+A and Closing)

Industry Symposia Program (Monday, April 19, 2021)

  • Examining primary hyperoxaluria type 1 and results from ILLUMINATE-A and ILLUMINATE-B clinical trials
  • Organizer: Alnylam Pharmaceuticals
  • Room: Room 2
  • Time: 08:00 – 09:00 EDT
  • Chair: Saland, Jeffrey (United States)
  • OPEN ACCESS CODE: LUYAMR99
  • Schedule:
    Time Title Speaker
    08:00–08:45 Examining primary hyperoxaluria type 1 and results from ILLUMINATE-A and ILLUMINATE-B clinical trials Saland, Jeffrey (United States)
    08:45–09:00 Questions and answers Saland, Jeffrey (United States)

  • New Insights in Alport Syndrome and Genetic Testing
  • Organizer: Reata Pharmaceuticals
  • Room: Room 1
  • Time: 08:00 – 09:00 EDT
  • Chairs: Torra, Roser (Spain) + Knebelmann, Bertrand (France)
  • OPEN ACCESS CODE: AUYIMR02
  • Schedule:
    Time Title Speaker
    08:00-08:10 How Alport Syndrome is Diagnosed and Triaged Torra, Roser (Spain)
    08:10-08:20 Classification/Disease Subtypes Torra, Roser (Spain)
    08:20-08:30 Genetics underlying the Disease and Prognosis Knebelmann, Bertrand (France)
    08:30-08:45 Case Studies in Alport Syndrome Knebelmann, Bertrand (France)
    08:45-09:00 Questions and Answers
Last updated: March 26, 2021